公开(公告)号：US20210169854A1

公开(公告)日：2021-06-10

申请号：US17025853

申请日：2020-09-18

Applicant: NOVARTIS AG

Inventor： Mangesh Sadashiv Bordawekar ,  Stephanie Kay Dodd ,  Cornelius Stephan Harlacher ,  Jithin K John ,  Pravin Karmuse ,  Saran Kumar ,  Sangeetha Kumari ,  Vishnu Maremanda ,  Parthkumar Patel ,  Kanhaiyalal Patidar ,  Kapil Patil ,  Alan Edward Royce ,  Shaikh Mohsin Shaikh Hamid ,  Mauro Serratoni ,  Henricus Lambertus Gerardus Maria Tiemessen ,  Daya D Verma ,  Sunita Yadav

IPC: A61K31/4152 ,  A61K47/22 ,  A61K9/48 ,  G01N33/15

Abstract: Disclosed are novel pharmaceutical formulation containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof and processes for preparing the same.

公开(公告)号：US11291661B2

公开(公告)日：2022-04-05

申请号：US16815183

申请日：2020-03-11

Applicant: NOVARTIS AG

Inventor： Geoffrey Gogniat ,  Saran Kumar ,  Ulrich Meier ,  Mario Rentsch

IPC: A61K31/46 ,  A61P1/16 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K9/50

Abstract: The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising an (a) inert substrate and a (b) mixture comprising a non-bile acid farnesoid X receptor (FXR) agonist, such as 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.